Bio-Rad's core operations have plateaued, with quarterly revenue hovering near $650M and growth between -0.1% and 3.9% over the past year, while operating margins have contracted from 15.9% in 2024Q2 to 11.2% in 2026Q2 due to rising SG&A and reduced R&D. The c...
Price trend, volume and key moving averages
Start with the evidence for owning the stock and the risks that can break the thesis.
Revenue growth has stalled at approximately $650M per quarter (latest -0.1% YoY), with gross margin stable at 53.1% but operating margin down to 11.2% from 15.9% two years ago, while net income swings wildly due to investment gains and losses (e.g., -$2.2B in 2024Q2 vs. $371.4M in 2026Q2).
Bio-Rad Laboratories is a global leader in life science research and clinical diagnostic markets, with a broad range of innovative products.
There is a bullish thesis on Bio-Rad Laboratories (BIO) highlighted by Stock Analysis Compilation, suggesting positive investor sentiment.
As of Nov 20th, BIO's forward P/E was 28.49, indicating potential value for investors based on earnings growth expectations.
Trailing total returns as of 10/3/2026, which may include dividends or other distributions. Benchmark is S&P 500 (^GSPC).
Check whether operating performance supports the current valuation.
Recent results and news deserve attention only when they alter the forward view.
| Quarter | EPS (Act vs Est) | Revenue (Act vs Est) |
|---|---|---|
Q3 2026Latest Aug 4, 2026 | $2.62+49.7% vs $1.75 | $651M+4.3% vs $624M |
Q2 2026 Apr 30, 2026 | $1.89-4.1% vs $1.97 | $592M+0.4% vs $590M |
Q1 2026 Feb 12, 2026 | $2.51-2.3% vs $2.57 | $693M+0.6% vs $689M |
Q4 2025 Oct 29, 2025 | $2.26-1.7% vs $2.30 | $653M-6.0% vs $695M |
Bio-Rad Laboratories NYSE: BIO is pursuing a multi-year effort to improve growth, expand margins and strengthen free cash flow, with management emphasizing portfolio focus, operating discipline and a more selective approach to acquisitions.
Bio-Rad Laboratories, Inc. (BIO) Presents at Bernstein Insights: Healthcare Leaders and Disruptors - 3rd Annual Healthcare Forum Transcript
BIO's Clinical Diagnostics strength and international reach support growth, while China weakness, geopolitics and FX remain key risks.
HOLMDEL, N.J., Sept. 23, 2026 (GLOBE NEWSWIRE) -- BIO-key® International, Inc. (NASDAQ: BKYI), a global provider of workforce and customer Identity and Access Management (IAM) software featuring passwordless, phoneless and tokenless Identity-Bound Biometrics™ (IBB) authentication, today announced that its Passkey:YOU™ authenticator has received Full Certification from the FIDO Alliance, the industry body behind the FIDO2/WebAuthn/Passkey standard now in widespread use to allow phish-resistant sign in without typing a password.
Benchmark BIO against direct peers instead of judging its metrics in isolation.
Key metrics vs top competitors for Bio-Rad Laboratories, Inc. (BIO)
| Company | Price | Market Cap | P/E Ratio | Rev Growth (1Y) | Net Margin | ROE | Div Yield |
|---|---|---|---|---|---|---|---|
| $369.14 | $9.94B | 13.25 | 0.65% | 29.42% | 10.84% | — | |
| $654.80 | $243.34B | 36.91 | 3.91% | 15.06% | 13.33% | — | |
| $214.06 | $150.48B | 42.47 | 2.9% | 15.95% | 7.66% | — | |
| $63.24 | $9.63B | -421.60 | 2.08% | -2.03% | -2.87% | — | |
| $181.70 | $10.25B | 211.28 | 16.36% | 5.29% | 1.98% | — | |
| $290.19 | $13.98B | -99.72 | -0.85% | -5.96% | -7.63% | — |
Bio-Rad Laboratories, Inc. (BIO) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
Verify the primary filings, follow material updates, and answer the remaining questions.
Bio-Rad Laboratories, Inc. (BIO) SEC filings — annual & quarterly reports (10-K, 10-Q)
Aug 4, 2026·SEC
Apr 30, 2026·SEC
Apr 24, 2026·SEC
Get notified when BIO posts new earnings or crosses analyst targets
Free. No account needed. Unsubscribe any time.
Bio-Rad Laboratories, Inc. (BIO) stock FAQ — growth, dividends, profitability & financials explained
Bio-Rad Laboratories, Inc. (BIO) reported $2.59B in revenue for fiscal year 2025. This represents a 518% increase from $418.8M in 1996.
Bio-Rad Laboratories, Inc. (BIO) grew revenue by 0.7% over the past year. Growth has been modest.
Yes, Bio-Rad Laboratories, Inc. (BIO) is profitable, generating $222.4M in net income for fiscal year 2025 (29.4% net margin).
Bio-Rad Laboratories, Inc. (BIO) has a return on equity (ROE) of 10.8%. This is reasonable for most industries.
Bio-Rad Laboratories, Inc. (BIO) generated $353.1M in free cash flow for fiscal year 2025. Positive FCF indicates the company can fund dividends, buybacks, or reinvestment.
